The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. T Cell Biology
Volume 16 - 2025 |
doi: 10.3389/fimmu.2025.1533254
This article is part of the Research Topic The Function and Regulation of T Cell Subsets in Inflammatory Disease View all 6 articles
Advance in Chimeric Antigen Receptor T therapy in Autoimmune Diseases
Provisionally accepted- 1 Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
- 2 First Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu Province, China
- 3 Suzhou University, Suzhou, Anhui, China
- 4 The First Clinical Medicine School, Suzhou Medical College, Suzhou, China
- 5 The Fourth Affiliated Hospital of Soochow University, Suzhou, China
- 6 Department of Ophthalmology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
Autoimmune diseases are a group of diseases in which the body's immune system misrecognizes its own antigens resulting in an abnormal immune response, which can lead to pathological damage to or abnormal functioning of its own tissues. Current treatments are mainly hormones and broad-spectrum immunosuppressants, but these can lead to a decline in the patient's immunity. Chimeric antigen receptor T (CAR-T) Cell therapy has emerged, and now the structure of CAR has changed from first generation to fourth generation of CAR. The significant achievement of CAR-T therapy to B-cell leukemia has also inspired the treatment of autoimmune diseases, and by investigating the mechanisms of different autoimmune diseases, different designs of CAR-T can be used to specifically treat autoimmune diseases. In this review, we will discuss the therapeutic strategies of CAR-T cells in different autoimmune diseases and the limitations of the treatment.
Keywords: CAR, t, Autoimmune Diseases, Immunotherapy, CAR-Treg, CAAR-T
Received: 23 Nov 2024; Accepted: 10 Feb 2025.
Copyright: © 2025 Ji, Sun, Xie, Gao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yunfan Sun, First Clinical Medical College, Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China
Yuyang Xie, Suzhou University, Suzhou, 234000, Anhui, China
Jianling Gao, The Fourth Affiliated Hospital of Soochow University, Suzhou, China
Ji Zhang, Department of Ophthalmology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.